生物标志物在晚期非小细胞肺癌免疫治疗中的预测价值  

Predictive value of biomarkers in immunotherapy of advanced non-small cell lung cancer

作　　者：雷艳 张革红[2] Lei Yan;Zhang Gehong(First Clinical College of Shanxi Medical University,Taiyuan 030001,China;Department of Oncology,First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一临床医学院,太原030001 [2]山西医科大学第一医院肿瘤科,太原030001

出　　处：《国际肿瘤学杂志》2022年第12期739-744,共6页Journal of International Oncology

摘　　要：免疫治疗尤其是免疫检查点抑制剂,彻底改变了晚期非小细胞肺癌的治疗模式。程序性死亡配体-1、肿瘤突变负荷对治疗反应的预测作用已得到充分证明,但其无法避免肿瘤异质性、检测方法及判读标准不一致等问题。研究发现一些新型生物标志物与免疫治疗疗效相关,如基因错配修复缺陷、微卫星不稳定性、驱动基因突变、外周血常规生物标志物、循环肿瘤细胞、循环肿瘤DNA等。进一步研究肿瘤组织和外周血的生物标志物在晚期非小细胞肺癌免疫治疗中的预测价值,可为治疗方案的选择提供参考。Immunotherapy,especially immune checkpoint inhibitor,has revolutionized the treatment mode of advanced non-small cell lung cancer.The predictive effect of programmed death-ligand 1 and tumor mutation burden for treatment response has been fully proved.Neither of which can avoid some problems,including tumor heterogeneity,inconsistent detection methods and identification standards.The studies have found that some novel biomarkers are related to the efficacy of immunotherapy,such as mismatch repair deficiency and microsatellite instability,driver gene mutation,routine peripheral blood biomarkers,circulating tumor cells,circulating tumor DNA and so on.Further research on the predictive value of biomarkers in tumor tissue and peripheral blood in immunotherapy of advanced non-small cell lung cancer can provide a reference for instituting clinical treatment plan.

关 键 词：癌 非小细胞肺 免疫检查点抑制剂 生物标志物 

分 类 号：R73[医药卫生—肿瘤]